http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2579230-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e61263b84630539d1fc5281e3bd9ac4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1b2710fc436b8878c41e7b12250bba5a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2005-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_799b9d10b6d3f57722a204d60d1b9d45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c5df4299c876da790fb86acce21a841e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9ca3e3425d2595b156b0628bc7e9f27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93f47710e3c298f14fec30c5829bec2a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e846555ee4a2b63439accf16ded8df5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1ed26ecc98ea756d0a37d9a8cc0e308 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_893f28f6e34f1cb26ae21c7e51c089b8 |
| publicationDate | 2006-03-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2579230-A1 |
| titleOfInvention | Fibrate compounds having ppar agonist activity |
| abstract | There are provided derivatives having PPAR agonist activity. The derivatives include compounds and/or their pharmaceutically acceptable salts; the compounds having the formula (I) wherein A has the structure (II) or (III); X is chosen from -CH2-, -O-, -NH-, and -S-; Y is chosen from -O-, -NH-, and -S-; Z, which may be located in any position of substitution, is hydrogen or halogen; R1 and R2, which may be the same or different, are independently chosen from hydrogen and C1-C8 alkyl, or R1 and R2 together form a carbocyclic ring having from 4 to 6 carbon atoms; R3 is chosen from hydrogen and C1-C8 alkyl; R4, R5, and R6, which may be the same or different, are independently chosen from hydrogen and C1-C8 alkyl; and n is 1 to 6. Various embodiments and variants are provided. In accordance with other aspects, the invention also provides methods of producing a PPAR.alpha. agonist activity in a mammal, the methods including administering to the mammal an effective amount of certain derivative(s) of the first aspect of the invention, a method of producing a PPAR.alpha. agonist activity and a PPAR.alpha. agonist activity in a mammal, the method including administering to the mammal an effective amount of certain derivative(s); and a pharmaceutical composition that includes the derivative(s) of the first aspect of the invention and one or more pharmaceutically-acceptable excipients. Various embodiments and variants are provided. |
| priorityDate | 2004-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 576.